Cargando…
Current progress in innovative engineered antibodies
As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 na...
Autor principal: | Strohl, William R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777977/ https://www.ncbi.nlm.nih.gov/pubmed/28822103 http://dx.doi.org/10.1007/s13238-017-0457-8 |
Ejemplares similares
-
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions
por: Kinder, Michelle, et al.
Publicado: (2015) -
The history of monoclonal antibody development – Progress, remaining challenges and future innovations
por: Liu, Justin K.H.
Publicado: (2014) -
Current progress in application of polymeric nanofibers to tissue engineering
por: Nemati, Sorour, et al.
Publicado: (2019) -
Current progress in hepatic tissue regeneration by tissue engineering
por: Hosseini, Vahid, et al.
Publicado: (2019) -
Current Progress in Vascular Engineering and Its Clinical Applications
por: Jouda, Hatem, et al.
Publicado: (2022)